Cue Biopharma, Inc. — Net Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/835b6783-1d0d-4424-acef-ea4185dadc16/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-26.6M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-108287 |
| FY 2024 | $-40.7M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-047677 |
| FY 2023 | $-50.7M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-038059 |
| FY 2022 | $-53.0M | 2022-01-01 – 2022-12-31 | evidence 0000950170-24-038059 |
| FY 2021 | $-44.2M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-003969 |
| FY 2020 | $-44.8M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-011777 |
| FY 2019 | $-36.7M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-010212 |
| FY 2018 | $-23.2M | 2017-01-01 – 2018-12-31 | evidence 0001564590-20-038375 |
| FY 2017 | $-23.2M | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-007832 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Cue Biopharma, Inc. — all facts · Revenue · Operating Income